| Name | Fluoxetine |
| Description | Fluoxetine (LY-110140) is a highly specific serotonin uptake inhibitor and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor. Fluoxetine has antidepressant activity. |
| In vitro | METHODS: Mouse cortical near-pure neuronal cell cultures were treated with Fluoxetine (3-30 µM) for 24 h. Cell viability was measured by MTT assay.
RESULTS: Fluoxetine induced neuronal death in a concentration-dependent manner. [1]
METHODS: Human gastric cancer cells AGS were treated with Fluoxetine (10-20 µM) for 24 h. Apoptosis was detected by Flow cytometry.
RESULTS: The number of early apoptotic cells in Fluoxetine-treated group was significantly increased by about 4-fold and 10-fold, respectively. [2] |
| In vivo | METHODS: To assay antidepressant activity in vivo, Fluoxetine (2.5-10 mg/kg) was administered intraperitoneally to MRL/MpJ mice twice daily for twenty-six days.
RESULTS: Chronic treatment with 5 and 10 mg/kg Fluoxetine significantly increased cell proliferation and BDNF levels in the hippocampus. Only chronic treatment with the highest Fluoxetine increased BDNF levels in the frontal cortex. [3]
METHODS: To test antidepressant activity in vivo, Fluoxetine (18 mg/kg) was administered orally once daily for three weeks to a model of corticosterone-induced anxiety/depression-like behavior in C57BL/6Ntac mice.
RESULTS: Chronic Fluoxetine treatment reversed the anxiety phenotype. Regarding total distance traveled, chronic corticosterone treatment showed a nonsignificant trend that was eliminated by chronic Fluoxetine treatment. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 5% DMSO+95% Saline : 0.3 mg/mL (0.97 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO : 10 mg/mL (32.33 mM), Sonication is recommended.
|
| Keywords | SLC6A4 | Sert (Sodium-dependent) | SERT | SerotoninTransporter | Serotonin Transporter | MRP1 | LY110140 | LY 110140 | Inhibitor | inhibit | Fluoxetine | Autophagy | 5-HTT | 5HTReceptor | 5HT Receptor |
| Inhibitors Related | Stavudine | Xylitol | Aceglutamide | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
